About Advera Health Analytics

Advera Health Analytics was founded in 2010 by a group of passionate healthcare data entrepreneurs. Our mission is to mitigate risk in the healthcare system by improving the transparency and actionability of drug safety data. We do this by aggregating and curating large disparate datasets and deploying proprietary analytics to provide insight on the safety of marketed and pipeline drugs. Our goal is to become the gold standard resource for drug safety knowledge and insight across clinical trials, spontaneous reporting, and other real world evidence.

Brian Overstreet

Brian M. Overstreet, President

As co-founder and President of Advera Health Analytics, Brian oversees the company’s growth strategy. Prior to Advera Health Analytics, Brian was a co-founder of Sagient Research Systems Inc. He served as the company's president and CEO from 1999 to 2009 and as the chairman of the board from 2010 until the company's acquisition in May 2012 by Informa plc.

Contact Brian |

Jim Davis

Jim Davis, Executive Vice President

Jim brings over 12 years of experience in commercial strategy, global sales management and execution, business development, and product development. He has over 9 years of specific domain expertise in biopharma market research, intelligence, and data. Prior to joining Advera Health, Jim served as the Global Head of Sales for the BioPharm Solutions Suite at Infinata, Inc. (A part of The Mergermarket Group, a Financial Times Group company and a division of Pearson, Plc.).

Contact Jim |

Robert Kyle

Robert Kyle, Chief Product Officer

As co-founder and Chief Product Officer of Advera Health Analytics, Inc., Bob Kyle is in charge of defining and driving the company’s product strategy and managing the product life cycle, from conception through launch. Bob’s product vision drives and inspires the company to continually innovate and rapidly adapt products to the changing needs of the marketplace. Executing consistently and effectively on product refinements and new releases ensures that the company's growth strategy is intertwined with that of its clients.

Contact Bob |

Henry Duong

Henry Duong, Chief Operating Officer

As co-founder and Chief Operating Officer of Advera Health Analytics, Henry is responsible for the day-to-day operations relating to accounting, technology, and human resources. Henry brings more than fifteen years of experience in operations and technical development management in the data, research, and investment industries.

Contact Henry |

Murali Doraiswamy, M.D., Duke University Health System

Dr. Doraiswamy is a professor in Psychiatry and Medicine at Duke University Medical Center and a leading expert in psychopharmacology, drug safety and clinical trials. He has coauthored more than 200 scientific articles and served as an advisor to the WHO, FDA, NIH, pharmaceutical companies and leading advocacy groups.

Greg Fiore, M.D., SSI Strategy

Dr. Fiore is president of SSI Strategy, which provided pharmaceutical management and pharmacovigilance consulting. Prior to SSI, Dr. Fiore was the Chief Medical Officer of The Medicines Company, a global pharmaceutical company focused on advancing the treatment of critical care patients. Dr. Fiore also held senior positions at Merck, Abbott Laboratories, and McKinsey Consulting.

Robert Harrington, M.D., Stanford University

Dr. Harrington is the new Chair of the Department of Medicine at Stanford University School of Medicine, effective July 2012. Prior to joining Stanford, Dr. Harrington was the director of the Duke Clinical Research institute, the largest academic clinical research organization in the world with a faculty of over 200 and a professional staff of over 1,100 that represents every major therapeutic area in medicine. Dr. Harrington’s research interests include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, studying the mechanism of disease of the acute coronary syndromes, understanding the issues of risk stratification in the care of patients with acute ischemic coronary syndromes, trying to better understand and improve upon the methodology of clinical trials.

Keith Hoffman, Ph.D., LA BioMed

Dr. Keith Hoffman was one of Advera Health’s earliest team members, serving as our VP Scientific Affairs from 2011 to 2016. During his tenure with the company, Dr. Hoffman was chiefly responsible for scientific validation and publication of our proprietary analytic tools, data mining technologies, and unique drug safety findings. Key publications included “A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes” (in the Journal of Managed Care & Specialty Pharmacy) and “A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports” (in the journal “Drug Safety.”)

Dr. Hoffman earned both his B.S. in Biology and Ph.D. in Neuroscience from UC Irvine in the laboratory of Dr. Gary Lynch. After his academic career he specialized in technology start-ups where he had 18 years of senior management roles (COO, CBO, VP) in business, corporate, science, and intellectual property development for biotechnology, healthcare data, medical device, and consumer product companies. In his new role as an active member of our Scientific Advisory Board, Dr. Hoffman continues to pursue scientific publications and contributions using Advera’s proprietary tools and suite of data.

Lawrence J. Lesko, Ph.D., University of Florida

Dr. Lawrence J. Lesko is Emeritus Professor and Founding Director of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida College of Pharmacy at Lake Nona (Orlando). He started the Center in 2011 and served as its Director until April 2016. Dr. Lesko was previously appointed as the first Director of the Office of Clinical Pharmacology in the Center for Drug Evaluation and Research at the Food and Drug Administration in 1995. His tenure was for 16 years until his retirement in July 2011. At the FDA, Dr. Lesko led the advancement of drug safety through personalized medicine and updating of labels of previously approved drugs with new genetic information. Dr. Lesko has published more than 200 peer-reviewed manuscripts and is a frequent invited national and international speaker. Dr. Lesko serves on the Scientific Advisor Boards of several non-profit and for-profit organizations and is a consultant to several pharmaceutical companies.

He was awarded the prestigious Global Gators Award by the University of Florida in 2017, and was also the recipient of the 2015 Leadership Award from the International Society of Pharmacometrics, the 2015 Agilent Technologies Thought Leader Award in Integrated Systems Toxicology and the 2014 AAPS Distinction in Biomarker Research Award. In 2011, he received the Gary Neil Prize for Innovation in Drug Development from the American Society of Clinical Pharmacology and Therapeutics (ASCPT). Dr. Lesko also was honored with the Rawls Palmer Progress in Medicine award from ASCPT, the Coriell Scientific Leadership Award for Personalized Medicine, the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy Award for Clinical Service, and the Nathanial B. Kwit Distinguished Service Award for Clinical Pharmacology from the American College of Clinical Pharmacology.

Nicholas Tatonetti, Ph.D., Columbia University

Dr. Nicholas Tatonetti trained in mathematics and molecular biology at Arizona State University before receiving his PhD in biomedical informatics in 2012 from Stanford University. His dissertation was focused on the development of novel statistical and computational methods for observational data mining. He applied these methods to drug safety surveillance where he discovered and validated new drug effects and interactions. In September 2012, Dr. Tatonetti joined the faculty as an Assistant Professor in the Departments of Biomedical Informatics, Systems Biology, and Medicine. Shortly after, he became Director for the Clinical Informatics Shared Resource (CISR) at the Herbert Irving Comprehensive Cancer Center. His lab at Columbia is focused on expanding upon his previous work in detecting, explaining, and validating drug effects and drug interactions from large-scale observational data.

Widely published in both clinical and bioinformatics, Dr. Tatonetti is passionate about the integration of hospital data (stored in the electronic health records) and high-dimensional biological data (captured using next-generation sequencing, high-throughput screening, and other "omics" technologies). His lab develops the algorithms, techniques, and methods for analyzing enormous and diverse data by designing rigorous computational and mathematical approaches that address the fundamental challenges of observational analysis -- bias and confounding. Foremost, they integrate medical observations with systems and chemical biology models to, not only, explain clinical effects, but also further our understanding basic biology and human disease. Dr. Tatonetti has been featured by the New York Times, Genome Web, and Science Careers. His work has been picked up by the mainstream and scientific media and generated hundreds of news articles.

October 8, 2015
April 16, 2014